Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 250

1.
2.

Comparison of 3D conformal radiation therapy and intensity-modulated radiation therapy in patients with endometrial cancer: efficacy, safety and prognostic analysis.

Ta MH, Schernberg A, Giraud P, Monnier L, Darai É, Bendifallah S, Schlienger M, Touboul E, Orthuon A, Challand T, Huguet F, Rivin Del Campo E.

Acta Oncol. 2019 Aug;58(8):1127-1134. doi: 10.1080/0284186X.2019.1599136. Epub 2019 Apr 24.

PMID:
31017032
3.

Glucocentric risk factors for macrovascular complications in diabetes: Glucose 'legacy' and 'variability'-what we see, know and try to comprehend.

Monnier L, Colette C, Schlienger JL, Bauduceau B, R Owens D.

Diabetes Metab. 2019 Jan 24. pii: S1262-3636(19)30022-9. doi: 10.1016/j.diabet.2019.01.007. [Epub ahead of print] Review.

PMID:
30685425
4.

Patterns of recurrence and prognosis in locally advanced FIGO stage IB2 to IIB cervical cancer: Retrospective multicentre study from the FRANCOGYN group.

de Foucher T, Bendifallah S, Ouldamer L, Bricou A, Lavoue V, Varinot J, Canlorbe G, Carcopino X, Raimond E, Monnier L, Graesslin O, Touboul C, Collinet P, Neveu ME, Huchon C, Daraï E, Ballester M; Groupe de Recherche Francogyn, France.

Eur J Surg Oncol. 2019 Apr;45(4):659-665. doi: 10.1016/j.ejso.2018.11.014. Epub 2018 Dec 30.

PMID:
30685326
5.

Combined reversible switching of ECD and quenching of CPL with chiral fluorescent macrocycles.

Homberg A, Brun E, Zinna F, Pascal S, Górecki M, Monnier L, Besnard C, Pescitelli G, Di Bari L, Lacour J.

Chem Sci. 2018 Aug 1;9(35):7043-7052. doi: 10.1039/c8sc02935k. eCollection 2018 Sep 21.

6.

Branched-Chain Amino Acid Database Integrated in MEDIPAD Software as a Tool for Nutritional Investigation of Mediterranean Populations.

Haydar S, Paillot T, Fagot C, Cogne Y, Fountas A, Tutuncu Y, Vintila M, Tsatsoulis A, Thanh Chi P, Garandeau P, Chetea D, Badiu C, Gheorghiu M, Ylli D, Lautier C, Jarec M, Monnier L, Normand C, Šarac J, Barakat A, Missoni S, Pugeat M, Poucheret P, Hanzu F, Gomis R, Macias JM, Litvinov S, Khusnutdinova E, Poiana C, Pasquali R, Lauro D, Sesti G, Trischitta V, Abdelhak S, Zenati A, Ylli A, Satman I, Kanninen T, Rinato Y, Grigorescu F.

Nutrients. 2018 Oct 1;10(10). pii: E1392. doi: 10.3390/nu10101392.

7.

Glycaemic variability in diabetes: clinical and therapeutic implications.

Ceriello A, Monnier L, Owens D.

Lancet Diabetes Endocrinol. 2019 Mar;7(3):221-230. doi: 10.1016/S2213-8587(18)30136-0. Epub 2018 Aug 13. Review.

PMID:
30115599
8.

The application of simple metrics in the assessment of glycaemic variability.

Monnier L, Colette C, Owens DR.

Diabetes Metab. 2018 Sep;44(4):313-319. doi: 10.1016/j.diabet.2018.02.008. Epub 2018 Mar 6. Review.

PMID:
29602622
9.

Association of postprandial and fasting plasma glucose with HbA1c across the spectrum of glycaemic impairment in type 2 diabetes.

Valensi P, Husemoen LLN, Weatherall J, Monnier L.

Int J Clin Pract. 2017 Dec;71(12). doi: 10.1111/ijcp.13041. No abstract available.

10.

Pharmacological variability of insulins degludec and glargine 300U/mL: Equivalent or not?

Monnier L, Colette C.

Diabetes Metab. 2018 Feb;44(1):1-3. doi: 10.1016/j.diabet.2017.11.001. Epub 2017 Nov 14. No abstract available.

PMID:
29196025
11.

Glucose variability: Do we have to revisit the profusion of definitions to avoid confusion?

Monnier L, Colette C, Owens D.

Diabetes Metab. 2018 Mar;44(2):97-100. doi: 10.1016/j.diabet.2017.10.005. Epub 2017 Nov 16. No abstract available.

PMID:
29153486
12.

Les traitements combinés dans les formes à haut risque évolutif du cancer de la prostate (localisé ou non).

Monnier L, Culine S, Cormier L.

Presse Med. 2017 Oct;46(10):940-947. doi: 10.1016/j.lpm.2017.03.007. Epub 2017 May 23. French.

PMID:
28549631
13.

Selexipag Active Metabolite ACT-333679 Displays Strong Anticontractile and Antiremodeling Effects but Low β-Arrestin Recruitment and Desensitization Potential.

Gatfield J, Menyhart K, Wanner D, Gnerre C, Monnier L, Morrison K, Hess P, Iglarz M, Clozel M, Nayler O.

J Pharmacol Exp Ther. 2017 Jul;362(1):186-199. doi: 10.1124/jpet.116.239665. Epub 2017 May 5.

PMID:
28476928
14.

A review of glucagon-like peptide-1 receptor agonists and their effects on lowering postprandial plasma glucose and cardiovascular outcomes in the treatment of type 2 diabetes mellitus.

Owens DR, Monnier L, Hanefeld M.

Diabetes Obes Metab. 2017 Dec;19(12):1645-1654. doi: 10.1111/dom.12998. Epub 2017 Jul 11. Review.

15.

Future challenges and therapeutic opportunities in type 2 diabetes: Changing the paradigm of current therapy.

Owens DR, Monnier L, Barnett AH.

Diabetes Obes Metab. 2017 Oct;19(10):1339-1352. doi: 10.1111/dom.12977. Epub 2017 Jun 9. Review.

16.

Anoperineal disease in Hidradenitis Suppurativa : MR imaging distinction from perianal Crohn's disease.

Monnier L, Dohan A, Amara N, Zagdanski AM, Drame M, Soyer P, Hoeffel C.

Eur Radiol. 2017 Oct;27(10):4100-4109. doi: 10.1007/s00330-017-4776-1. Epub 2017 Mar 13.

PMID:
28289934
17.

Toward Defining the Threshold Between Low and High Glucose Variability in Diabetes.

Monnier L, Colette C, Wojtusciszyn A, Dejager S, Renard E, Molinari N, Owens DR.

Diabetes Care. 2017 Jul;40(7):832-838. doi: 10.2337/dc16-1769. Epub 2016 Dec 30.

PMID:
28039172
18.

Individualized, patient-centered use of lixisenatide for the treatment of type 2 diabetes mellitus.

Hanefeld M, Raccah D, Monnier L.

Expert Opin Drug Metab Toxicol. 2017 Mar;13(3):311-321. doi: 10.1080/17425255.2017.1251579. Epub 2016 Nov 3. Review.

PMID:
27776453
20.

Tailoring nutrient sequence and content to improve glucose tolerance: Why and how to do it.

Monnier L, Bonnet F, Colette C.

Diabetes Metab. 2016 Sep;42(4):211-4. doi: 10.1016/j.diabet.2016.04.003. Epub 2016 May 13. No abstract available.

PMID:
27184768
21.

Two phases of aging separated by the Smurf transition as a public path to death.

Dambroise E, Monnier L, Ruisheng L, Aguilaniu H, Joly JS, Tricoire H, Rera M.

Sci Rep. 2016 Mar 22;6:23523. doi: 10.1038/srep23523.

22.

Early Treatment with Basal Insulin Glargine in People with Type 2 Diabetes: Lessons from ORIGIN and Other Cardiovascular Trials.

Hanefeld M, Monnier L, Schnell O, Owens D.

Diabetes Ther. 2016 Jun;7(2):187-201. doi: 10.1007/s13300-016-0153-3. Epub 2016 Feb 10. Review.

23.

[Stage IB2, IIA and IIB cervical carcinoma without lymph node extension treated with neoadjuvant chemoradiotherapy].

Monnier L, Touboul E, Daraï E, Lefranc JP, Lauratet B, Ballester M, Huguet F.

Bull Cancer. 2016 Feb;103(2):164-72. doi: 10.1016/j.bulcan.2015.11.010. Epub 2016 Jan 25. French.

PMID:
26822905
24.

Near normal HbA1c with stable glucose homeostasis: the ultimate target/aim of diabetes therapy.

Monnier L, Colette C, Dejager S, Owens DR.

Rev Endocr Metab Disord. 2016 Mar;17(1):91-101. doi: 10.1007/s11154-016-9325-8. Review.

PMID:
26803295
25.

Postprandial and basal hyperglycaemia in type 2 diabetes: Contributions to overall glucose exposure and diabetic complications.

Monnier L, Colette C.

Diabetes Metab. 2015 Dec;41(6 Suppl 1):6S9-6S15. doi: 10.1016/S1262-3636(16)30003-9.

PMID:
26774019
26.

The new long-acting insulin glargine U300 achieves an early steady state with low risk of accumulation.

Monnier L, Owens DR, Bolli GB.

Diabetes Metab. 2016 Apr;42(2):77-9. doi: 10.1016/j.diabet.2015.11.005. Epub 2015 Dec 10. No abstract available.

PMID:
26688145
27.

Ramadan and diabetes: What we see, learn and understand from continuous glucose monitoring.

Monnier L, El Azrak A, Lessan N, Rochd D, Colette C, Bonnet F.

Diabetes Metab. 2015 Dec;41(6):456-62. doi: 10.1016/j.diabet.2015.09.002. Epub 2015 Oct 23. Review.

PMID:
26476619
28.

Association of HbA1c variability with atherosclerosis in diabetes: simple marker, risk factor or statistical bias?

Monnier L, Colette C.

J Diabetes Complications. 2015 Aug;29(6):745-6. doi: 10.1016/j.jdiacomp.2015.05.002. Epub 2015 May 7. No abstract available.

PMID:
26082425
29.

[Ductal carcinoma in situ treated with radiation therapy and additional boost].

Geiss R, Cabel L, Touboul E, Lefranc JP, Daraï É, Lauratet B, Monnier L, Haberer-Guillerm S, Deluen F, Schlienger M, Huguet F.

Cancer Radiother. 2015 May;19(3):175-9. doi: 10.1016/j.canrad.2015.01.002. Epub 2015 Apr 25. French.

PMID:
25921619
30.

Using the respective contributions of postprandial and basal glucose for tailoring treatments in type 2 diabetes.

Monnier L, Colette C.

Diabetes Metab. 2015 Jun;41(3):179-82. doi: 10.1016/j.diabet.2015.03.004. Epub 2015 Apr 17. No abstract available.

PMID:
25900889
31.

FTY720 Phosphate Activates Sphingosine-1-Phosphate Receptor 2 and Selectively Couples to Gα12/13/Rho/ROCK to Induce Myofibroblast Contraction.

Sobel K, Monnier L, Menyhart K, Bolinger M, Studer R, Nayler O, Gatfield J.

Mol Pharmacol. 2015 Jun;87(6):916-27. doi: 10.1124/mol.114.097261. Epub 2015 Mar 11.

PMID:
25762025
32.

"Mild dysglycemia" in type 2 diabetes: to be neglected or not?

Monnier L, Colette C, Dejager S, Owens DR.

J Diabetes Complications. 2015 Apr;29(3):451-8. doi: 10.1016/j.jdiacomp.2014.12.004. Epub 2014 Dec 12. Review.

PMID:
25572605
33.

New insights on glucose homoeostasis during Ramadan.

Monnier L, Bonnet F, Colette C.

Diabetes Metab. 2015 Feb;41(1):1-4. doi: 10.1016/j.diabet.2014.11.005. Epub 2014 Dec 15. No abstract available.

PMID:
25523359
35.

The dawn phenomenon in type 2 diabetes: how to assess it in clinical practice?

Monnier L, Colette C, Dejager S, Owens D.

Diabetes Metab. 2015 Apr;41(2):132-7. doi: 10.1016/j.diabet.2014.10.002. Epub 2014 Nov 6.

PMID:
25457475
36.

Response to comment on Monnier et al. Magnitude of the dawn phenomenon and its impact on the overall glucose exposure in type 2 diabetes: is this of concern? Diabetes Care 2013;36:4057-4062.

Monnier L, Colette C, Dejager S, Owens D.

Diabetes Care. 2014 Jul;37(7):e163. doi: 10.2337/dc14-0609. No abstract available.

PMID:
24963117
37.

Self-monitoring of blood glucose: a prerequisite for diabetes management in outcome trials.

Schnell O, Hanefeld M, Monnier L.

J Diabetes Sci Technol. 2014 May;8(3):609-14. doi: 10.1177/1932296814528134. Epub 2014 Apr 2.

38.

Glycaemic variability and ambient hyperglycaemia: how and when are they linked?

Monnier L, Colette C.

Diabetes Metab. 2014 Sep;40(4):237-40. doi: 10.1016/j.diabet.2014.04.003. Epub 2014 May 19. No abstract available.

PMID:
24852510
39.

Residual dysglycemia when at target HbA(1c) of 7% (53mmol/mol) in persons with type 2 diabetes.

Monnier L, Colette C, Dejager S, Owens D.

Diabetes Res Clin Pract. 2014 Jun;104(3):370-5. doi: 10.1016/j.diabres.2014.03.012. Epub 2014 Mar 28.

PMID:
24735710
40.

Sphingosine-1-phosphate (S1P) displays sustained S1P1 receptor agonism and signaling through S1P lyase-dependent receptor recycling.

Gatfield J, Monnier L, Studer R, Bolli MH, Steiner B, Nayler O.

Cell Signal. 2014 Jul;26(7):1576-88. doi: 10.1016/j.cellsig.2014.03.029. Epub 2014 Apr 2.

PMID:
24704119
41.

[Isolated pelvic recurrences of cervical carcinoma treated with salvage chemoradiotherapy].

Besson N, Touboul E, Daraï É, Lefranc JP, Monnier L, Schlienger M, Huguet F.

Cancer Radiother. 2014 Mar;18(2):83-8. doi: 10.1016/j.canrad.2013.11.010. Epub 2014 Jan 24. French.

PMID:
24462252
42.

Magnitude of the dawn phenomenon and its impact on the overall glucose exposure in type 2 diabetes: is this of concern?

Monnier L, Colette C, Dejager S, Owens D.

Diabetes Care. 2013 Dec;36(12):4057-62. doi: 10.2337/dc12-2127. Epub 2013 Oct 29.

43.

Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus.

Owens DR, Monnier L, Bolli GB.

Diabetes Metab. 2013 Dec;39(6):485-96. doi: 10.1016/j.diabet.2013.09.004. Epub 2013 Oct 22. Review.

PMID:
24156868
44.

Basal insulin analogs: from pathophysiology to therapy. What we see, know, and try to comprehend?

Monnier L, Colette C, Owens D.

Diabetes Metab. 2013 Dec;39(6):468-76. doi: 10.1016/j.diabet.2013.09.003. Epub 2013 Oct 17. Review.

PMID:
24139826
45.

Basal insulin analogues in the management of diabetes mellitus: What progress have we made?

Owens DR, Matfin G, Monnier L.

Diabetes Metab Res Rev. 2014 Feb;30(2):104-19. doi: 10.1002/dmrr.2469. Review.

PMID:
24026961
46.

The role of completion surgery after concurrent radiochemotherapy in locally advanced stages IB2-IIB cervical cancer.

Chereau E, DE LA Hosseraye C, Ballester M, Monnier L, Rouzier R, Touboul E, Daraï E.

Anticancer Res. 2013 Apr;33(4):1661-6.

PMID:
23564812
47.

Insulin and atherosclerosis: how are they related?

Monnier L, Hanefeld M, Schnell O, Colette C, Owens D.

Diabetes Metab. 2013 Apr;39(2):111-7. doi: 10.1016/j.diabet.2013.02.001. Epub 2013 Mar 15. Review.

PMID:
23507269
48.

Hypofractionated palliative radiotherapy for advanced head and neck cancer: the IHF2SQ regimen.

Monnier L, Touboul E, Durdux C, Lang P, St Guily JL, Huguet F.

Head Neck. 2013 Dec;35(12):1683-8. doi: 10.1002/hed.23219. Epub 2013 Jan 29.

PMID:
23359352
49.

Comparison of stepwise addition of prandial insulin to a basal-bolus regimen when basal insulin is insufficient for glycaemic control in type 2 diabetes: results of the OSIRIS study.

Raccah D, Haak TJ, Huet D, Monnier L, Robertson D, Labard P, Soler J, Penfornis A.

Diabetes Metab. 2012 Dec;38(6):507-14. doi: 10.1016/j.diabet.2012.08.010. Epub 2012 Oct 30.

PMID:
23116646
50.

Frequency and severity of the dawn phenomenon in type 2 diabetes: relationship to age.

Monnier L, Colette C, Sardinoux M, Baptista G, Regnier-Zerbib A, Owens D.

Diabetes Care. 2012 Dec;35(12):2597-9. doi: 10.2337/dc12-0385. Epub 2012 Sep 18.

Supplemental Content

Loading ...
Support Center